Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells $1,274,898.75 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 14,205 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total value of $1,274,898.75. Following the transaction, the insider directly owned 105,141 shares in the company, valued at approximately $9,436,404.75. The trade was a 11.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dennis Cho also recently made the following trade(s):

• On Monday, June 22nd, Dennis Cho sold 346 shares of Twist Bioscience stock. The stock was sold at an average price of $87.32, for a total value of $30,212.72.
• On Monday, June 8th, Dennis Cho sold 402 shares of Twist Bioscience stock. The stock was sold at an average price of $69.84, for a total value of $28,075.68.

Twist Bioscience Stock Up 3.3%

Shares of TWST stock traded up $3.19 during trading hours on Friday, reaching $99.84. 4,274,502 shares of the company’s stock were exchanged, compared to its average volume of 1,512,186. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $104.23. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. The stock has a market cap of $6.22 billion, a PE ratio of -75.07 and a beta of 2.23. The stock’s fifty day moving average price is $66.16 and its two-hundred day moving average price is $51.10.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The company had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The business’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.66) earnings per share. Research analysts predict that Twist Bioscience Corporation will post -2.02 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TWST. Western Wealth Management LLC purchased a new stake in shares of Twist Bioscience during the first quarter worth approximately $31,000. Strs Ohio purchased a new stake in Twist Bioscience during the 1st quarter valued at about $33,000. PNC Financial Services Group Inc. raised its holdings in Twist Bioscience by 89.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after acquiring an additional 453 shares during the last quarter. Quarry LP purchased a new stake in shares of Twist Bioscience in the third quarter valued at approximately $28,000. Finally, Strategic Advocates LLC increased its holdings in shares of Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after purchasing an additional 906 shares during the last quarter.

Wall Street Analyst Weigh In

TWST has been the topic of a number of research analyst reports. UBS Group set a $89.00 price objective on shares of Twist Bioscience in a report on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday. Piper Sandler initiated coverage on shares of Twist Bioscience in a report on Thursday, June 11th. They issued an “overweight” rating and a $85.00 price target on the stock. Canaccord Genuity Group started coverage on Twist Bioscience in a report on Monday, June 15th. They issued a “buy” rating and a $90.00 price objective for the company. Finally, TD Cowen lifted their price target on Twist Bioscience from $68.00 to $89.00 and gave the company a “buy” rating in a research report on Monday, June 15th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and an average price target of $74.60.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.